Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2022.03.02.22271731: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Study recruitment: This study was approved by the Mass General Brigham institutional review board under protocol 2021P000812.
Consent: Informed consent was obtained from all participants prior to initiating study procedures.
Field Sample Permit: Specimens were transported to the laboratory within four hours of collection.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources ELISA assays were performed using the Elecsys Anti-SARS-CoV-2 ELISA assays for Spike and Nucleocapsid antibodies as per manufacturer instructions (presumed wild type). Anti-SARS-CoV-2suggested: NoneResults from Od…
SciScore for 10.1101/2022.03.02.22271731: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Study recruitment: This study was approved by the Mass General Brigham institutional review board under protocol 2021P000812.
Consent: Informed consent was obtained from all participants prior to initiating study procedures.
Field Sample Permit: Specimens were transported to the laboratory within four hours of collection.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources ELISA assays were performed using the Elecsys Anti-SARS-CoV-2 ELISA assays for Spike and Nucleocapsid antibodies as per manufacturer instructions (presumed wild type). Anti-SARS-CoV-2suggested: NoneResults from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
